References
- Aurer I, Radman I, Nemet D, Zupancić-Salek S, Bogdanić V, Mrsić M, et al. Gemcitabine in the treatment of relapsed and refractory Hodgkin's disease. Onkologie 2005; 28: 567–571
- Baldwin S A, Beal P R, Yao S Y, King A E, Cass C E, Young J D. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447: 735–743
- Mackey J R, Baldwin S A, Young J D, Cass C E. The role of nucleoside transport in anticancer drug resistance. Drug Resistance Updates 1998; 1: 310–324
- Mackey J R, Mani R S, Selner M, Mowles D, Young J D, Belt J A, et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 1998; 58: 4349–4357
- Mackey J R, Yao S YM, Smith K M, et al. Gemcitabine transport in Xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters. J Natl Cancer Inst 1999; 91: 1876–1881
- Wiley J S, Taupin J, Jamieson G P, Snook M, Sawyer W H, Finch L R. Cytosine arabinoside transport and metabolism in acute leukemias and T cell lymphoblastic lymphoma. J Clin Invest 1985; 75: 632–642
- Boumah C E, Hogue D L, Cass C E. Expression of high levels of nitrobenzylthioinosine-sensitive nucleoside transport in cultured human choriocarcinoma (BeWo) cells. Biochem J 1992; 288: 987–996
- Reiman T, Graham K A, Wong J, Belch A R, Coupland R, Young J, et al. Mechanisms of resistance to nucleoside analogue chemotherapy in mantle cell lymphoma: a molecular case study. Leukemia 2002; 16: 1886–1887
- Spratlin J, Sangha R, Glubrecht D, Dabbagh L, Young J D, Dumontet C, et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 2004; 10: 6956–6961
- Chow L, Lai R, Dabbagh L, Belch A, Young J D, Cass C E, et al. Analysis of human equilibrative nucleoside transporter 1 (hENT1) protein in non-Hodgkin's lymphoma by immunohistochemistry. Mod Pathol 2005; 18: 558–564
- Reiman T, Clarke M L, Dabbagh L, Vsianska M, Coupland R W, Belch A R, et al. Differential expression of human equilibrative nucleoside transporter 1 (hENT1) protein in the Reed–Sternberg cells of Hodgkin's disease. Leuk Lymphoma 2002; 43: 1435–1440
- Wiley J S, Jones S P, Sawyer W H. Cytosine arabinoside transport by human leukemic cells. Eur J Cancer Clin Oncol 1983; 19: 1067–1074
- Barlett N L, Niedzwiecki D, Johnson J L, Friedberg J W, Johnson K B, van Besien K, et al. Gemcitabine, Vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's Lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071–1079
- Cass C E, Dahlig E, Lau E Y, Lynch T P, Paterson A RP. Fluctuations in nucleoside uptake and binding if the inhibitor of nucleoside transport, nitrobenzylthioinosine, during the replication cycle of HeLa cells. Cancer Res 1979; 39: 1245–1252
- Smith C L, Pilarski L M, Egerton M L, Wiley J S. Nucleoside transport and proliferative rate in human thymocytes and lymphocytes. Blood 1989; 74: 2038–2042